Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing peptide therapeutics for treating rare genetic disorders that cause life-threatening metabolic issues. Its lead product candidate, setmelanotide, is a potent melanocortin-4 receptor agonist designed for precision medicine to treat hyperphagia and severe obesity resulting from rare MC4R pathway diseases.
Top Stages
1 past transactions
Xinvento
Acquisition in 2023
Xinvento develops therapeutics for congenital hyperinsulinism, aiming to cure the condition by regulating insulin secretion and preventing related complications such as seizures, coma, brain damage, or death.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.